Funding for this research was provided by:
Cancerfonden (CAN 2018/685)
Fru Berta Kamprads Stiftelse (2020-5-282)
Received: 19 October 2020
Accepted: 11 January 2021
First Online: 10 February 2021
Change Date: 24 February 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/S13058-021-01405-Y
Ethics approval and consent to participate
: All included patients were enrolled in the Sweden Cancerome Analysis Network – Breast (SCAN-B) study (ExternalRef removed ID NCT02306096) [CitationRef removed–CitationRef removed], approved by the Regional Ethical Review Board in Lund, Sweden (Registration numbers 2009/658, 2010/383, 2012/58, 2016/742, 2018/267 and 2019/01252) as previously described [CitationRef removed]. All patients provided written informed consent prior to enrolment. All analyses were performed in accordance with local and international regulations for research ethics in human subject research.
: Not applicable.
: The authors declare that they have no competing interests with exception of Johan Hartman who has received speakers’ honoraria and travel support from Roche, advisory board fees from MSD, Novartis, and Roche, and institutional research grants from Cepheid and Novartis, and is the co-founder and shareholder of Stratipath AB.